Head-to-Head Trial Finds Winner for CRSwNP With Asthma
, 2025-06-24 10:41:00 Dupilumab significantly outperformed omalizumab in reducing the size of nasal polyps and improving sense of smell in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma, according to the head-to-head EVEREST phase 4 biologics trial. The study is the first to demonstrate the superiority of dupilumab over omalizumab across…